Holmes Joseph R. 4

What Happened
Joseph R. Holmes, Vice President & Chief Accounting Officer of Thermo Fisher Scientific (TMO), was awarded a total of 1,755 equity units on February 25, 2026. The filing shows three acquisitions at $0.00: 433 shares (performance-based RSUs), 337 shares (adjustment to a prior performance RSU tranche), and 985 units reported as a derivative (an option award). The Form 4 reports $0.00 as the acquisition price (typical for RSU/option grants); no immediate cash transaction was reported.

Key Details

• Transaction date: February 25, 2026. Form filed: February 27, 2026 (timely).
• Reported acquisitions: 433 shares @ $0.00 (F1); 337 shares @ $0.00 (F2); 985 units @ $0.00 (derivative, F3). Total = 1,755 units.
• Footnote highlights:
  • F1: 433 RSUs granted Feb 19, 2025; Compensation Committee certified performance on Feb 25, 2026. One‑third vests Feb 28, 2026 and 2027; final third vests Feb 28, 2028 and is subject to positive/negative adjustment tied to relative TSR vs. peers over 1/1/2025–12/31/2027.
  • F2: 337 shares are an adjustment to a Feb 22, 2023 performance RSU; Committee certified a 15% reduction for relative TSR, which equals 6 fewer shares than previously reported.
  • F3: The 985-unit derivative appears to be an option that vests in four equal annual installments beginning Feb 28, 2027.
• Shares owned after the reported transactions: not specified in the filing.
• Exhibit listed: Exhibit 24 — Power of Attorney.

Context
These are compensation awards (performance-based RSUs and an option-style award), not open-market purchases or sales. RSUs convert to shares only upon vesting and performance certification; the derivative award vests over future years. Such grants are a routine part of executive compensation and do not by themselves indicate a buy/sell decision by the insider.